{"product_id":"elekta-swot-analysis","title":"Elekta SWOT Analysis","description":"\u003cdiv class=\"pr-shrt-dscr-wrapper orange\"\u003e\n\u003csection class=\"pr-shrt-dscr-box\"\u003e\n\u003cdiv class=\"pr-shrt-dscr-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Magnifier-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eYour Strategic Toolkit Starts Here\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"pr-shrt-dscr-content\"\u003e\n\u003cp\u003eElekta’s innovation-led position in oncology and neurosurgery gives it a strong competitive edge, but regulatory hurdles and reimbursement pressures pose clear risks; our full SWOT unpacks these dynamics with market‑level financial context and strategic recommendations. Purchase the complete SWOT analysis to access a professionally written, editable Word report and Excel matrix—ready for investment decisions, strategy planning, or stakeholder presentations.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter green\"\u003eS\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003etrengths\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper green\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Strengths-Lightning-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eLeadership in MR-Linac Innovation\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eThe Elekta Unity MR-Linac pairs a 1.5T MRI with a 7MV linac, giving live tumor imaging and adaptive dosing; trials showed a 30–40% reduction in planning margins versus CT-guided therapy. By end-2025 Elekta had installed ~120 systems worldwide, driving 2025 MR-Linac revenue to an estimated $220–250M and positioning Elekta as a market leader in high-end adaptive radiotherapy.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Strengths-Lightning-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eDominance in Stereotactic Radiosurgery\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eThe Leksell Gamma Knife remains the global gold standard for non-invasive brain surgery, with Elekta holding an estimated 60–70% share of the stereotactic radiosurgery market for intracranial treatments as of 2025, per company disclosures and industry reports. This dominance targets complex neurological cases and creates high switching costs for hospitals due to specialized training and facility fit-outs. Recurring revenue from service, source replacements, and upgrades drove Elekta’s 2024 service \u0026amp; consumables segment to ~35% of group revenue (€1.1bn of €3.1bn). \u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Strengths-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Strengths-Lightning-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eIntegrated Oncology Informatics Suite\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eMOSAIQ, Elekta’s oncology information system, integrates EHR, treatment planning, and RT workflow, managing care for over 5,000 clinics globally as of 2025 and supporting \u0026gt;30% of Elekta device workflows; this unified platform reduces admin time, improves throughput, and locks in long-term service contracts, driving recurring software revenue (Elekta reported SEK 5.2bn software \u0026amp; services in 2024), strengthening customer stickiness across vendors and departments.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Strengths-Lightning-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eStrong Global Installed Base\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cpwith over systems installed globally as of elekta large base drives recurring revenue contracts and software updates accounted for roughly revenues predictable cash flow higher lifetime value per customer.\u003e\n\u003cpthis footprint gives elekta a ready market for product launches and modular hardware upgrades shortening sales cycles raising attach rates geographic diversity across countries reduces exposure to single-market downturns.\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003e~7,500 systems worldwide (2025)\u003c\/li\u003e\n\u003cli\u003eService\/software ~35% of 2024 revenue\u003c\/li\u003e\n\u003cli\u003ePresence in 70+ countries\u003c\/li\u003e\n\u003cli\u003eSupports faster product uptake and stable cash flow\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/pthis\u003e\u003c\/pwith\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Strengths-Lightning-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eStrategic Academic and Clinical Partnerships\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eElekta partners with top cancer centers and research institutions, funding trials and co-developing tech—over 200 peer-reviewed studies since 2020 and \u0026gt;15 clinical collaborations active in 2024—driving clinical evidence and faster regulatory wins.\u003c\/p\u003e\n\u003cp\u003eThese alliances keep Elekta aligned with clinical trends, supply real-world feedback for product iterations, and boost credibility; hospitals using Elekta report shorter implementation cycles and higher clinician satisfaction.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003e200+ peer-reviewed studies since 2020\u003c\/li\u003e\n\u003cli\u003e15+ active clinical collaborations in 2024\u003c\/li\u003e\n\u003cli\u003eFaster regulatory approvals via trial partnerships\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Strengths-Lightning-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eElekta: MR‑Linac \u0026amp; Gamma Knife leader with 7.5k systems, $220–250M MR sales, 35% recurring\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eElekta leads in adaptive radiotherapy (Unity MR‑Linac: ~120 installs by end‑2025; MR‑Linac revenue $220–250M in 2025), dominates stereotactic radiosurgery (Gamma Knife ~60–70% share), and has a large installed base (~7,500 systems, presence in 70+ countries) driving recurring service\/software (~35% of 2024 revenue) and strong clinical partnerships (200+ studies since 2020).\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eMetric\u003c\/th\u003e\n\u003cth\u003eValue\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eInstalled systems (2025)\u003c\/td\u003e\n\u003ctd\u003e~7,500\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eUnity MR‑Linac installs (end‑2025)\u003c\/td\u003e\n\u003ctd\u003e~120\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eMR‑Linac revenue (2025 est.)\u003c\/td\u003e\n\u003ctd\u003e$220–250M\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eGamma Knife market share (SRS, 2025)\u003c\/td\u003e\n\u003ctd\u003e60–70%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eService\/software share (2024)\u003c\/td\u003e\n\u003ctd\u003e~35% (€1.1bn of €3.1bn)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003ePeer‑reviewed studies since 2020\u003c\/td\u003e\n\u003ctd\u003e200+\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-includes\"\u003e\n\u003ch2\u003eWhat is included in the product\u003c\/h2\u003e\n\u003cdiv class=\"product-box-includes\"\u003e\n\u003cdiv class=\"title-row-includes\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Word-Icon.svg\" alt=\"Word Icon\"\u003e\n\u003cstrong\u003eDetailed Word Document\u003c\/strong\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-includes\"\u003e\n\u003cp\u003eProvides a concise SWOT overview of Elekta, highlighting its technological strengths and global footprint, operational and regulatory weaknesses, growth opportunities in oncology and radiotherapy innovation, and market threats from competition and healthcare policy shifts.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"plus-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Plus-Icon.svg\" alt=\"Plus Icon\"\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-includes\"\u003e\n\u003cdiv class=\"title-row-includes\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Excel-Icon.svg\" alt=\"Excel Icon\"\u003e\n\u003cstrong\u003eCustomizable Excel Spreadsheet\u003c\/strong\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-includes\"\u003e\n\u003cp\u003eProvides a concise Elekta SWOT snapshot for rapid strategic alignment and stakeholder-ready presentations.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-2_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter orange\"\u003eW\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003eeaknesses\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper orange\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Weaknesses-Cloud-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eOperating Margin Pressure\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eDespite 12% revenue growth in FY2024, Elekta’s operating margin lagged peers at 9.5% versus Varian (Siemens Healthineers) at ~18%; high R\u0026amp;D spend of SEK 3.4bn (2024) and component inflation (~6%–8% headwinds in 2024–25) squeezed profits.\u003c\/p\u003e\n\u003cp\u003eThe company cut SEK 500m in costs through 2025 programs but still targets mid-teens margins to match leaders; progress depends on supply-chain deflation and sustaining product mix shifts.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Weaknesses-Cloud-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eHeavy Reliance on Capital Expenditure Cycles\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eThe business depends on hospitals securing funding for expensive capital equipment; Elekta’s FY2024 orders fell 9% as European hospital capex tightened, showing sensitivity to funding cycles.\u003c\/p\u003e\n\u003cp\u003eHigh interest rates and tighter government budgets lengthen linac sales cycles; industry reports in 2024 showed purchasing lead times rising by 20–30% versus 2021.\u003c\/p\u003e\n\u003cp\u003eThis creates quarterly earnings volatility—Elekta’s Q3 2024 organic growth swung ±7% year-over-year—and complicates multi-year cash-flow forecasts for investors.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-2_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Weaknesses-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Weaknesses-Cloud-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eComplexity of Software Integration\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eWhile Elekta provides robust informatics, integrating legacy systems and third-party software still causes issues for some users; a 2024 customer survey showed 28% reporting interoperability problems across device generations. Customers report mismatches between older Elekta hardware and newer digital health platforms, increasing service calls by about 12% year-over-year in 2023. This friction has slowed adoption of new software modules among existing clients, contributing to a reported 6% lower upgrade rate in 2024 versus greenfield sales.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-orange-section\"\u003e\n\u003cdiv class=\"product-box-orange-section4\"\u003e\n\u003cdiv class=\"title-row-orange-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Weaknesses-Cloud-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eMarket Share Lag Against Varian\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n\u003cp\u003eElekta trails Varian Medical Systems (now part of Siemens Healthineers), holding roughly 30–35% share of the global linear accelerator (linac) market versus Varian’s ~50% as of 2024, forcing faster product innovation and aggressive pricing to win large hospital tenders.\u003c\/p\u003e\n\u003cp\u003eThis second-place position risks further share erosion in North America and APAC unless Elekta increases R\u0026amp;D spend (2024 R\u0026amp;D ~SEK 1.2bn) and sharpens tender strategies.\u003c\/p\u003e\n\u003cp\u003e\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eMarket share: Elekta ~30–35%, Varian ~50% (2024)\u003c\/li\u003e\n\u003cli\u003eR\u0026amp;D pressure: Elekta R\u0026amp;D ~SEK 1.2bn (2024)\u003c\/li\u003e\n\u003cli\u003eRisk: tender losses in North America\/APAC\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-orange-section4\"\u003e\n\u003cdiv class=\"title-row-orange-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Weaknesses-Cloud-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eSupply Chain Sensitivity for Specialized Components\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n\u003cpelekta machines rely on niche semiconductors and medical magnets from few suppliers supply shocks raised component costs by delayed shipments cutting fy2023 organic order intake growth\u003e\u003cpthe bottleneck risks production slowdowns and margin pressure if single parts or logistics hiccups recur.\u003e\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003e2023: component cost +8%\u003c\/li\u003e\n\u003cli\u003eFY2023: order intake growth -3.5%\u003c\/li\u003e\n\u003cli\u003eHigh single‑supplier dependency\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/pthe\u003e\u003c\/pelekta\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Weaknesses-Cloud-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eElekta margin compression: heavy R\u0026amp;D, falling orders and supply‑chain cost shocks\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eElekta’s operating margin lagged peers at 9.5% vs Varian\/Siemens ~18% (FY2024); R\u0026amp;D ~SEK 1.2bn (2024) and SEK 3.4bn company R\u0026amp;D\/innovation spend strained profits; FY2024 orders -9% as European hospital capex tightened; supply-chain shocks (component costs +8% in 2023) and single‑supplier risks slow production and raise margin volatility.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eMetric\u003c\/th\u003e\n\u003cth\u003eValue\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eOperating margin (FY2024)\u003c\/td\u003e\n\u003ctd\u003e9.5%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eVarian\/Siemens margin (FY2024)\u003c\/td\u003e\n\u003ctd\u003e~18%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eCompany R\u0026amp;D (2024)\u003c\/td\u003e\n\u003ctd\u003eSEK 1.2bn\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eTotal R\u0026amp;D\/innovation spend (2024)\u003c\/td\u003e\n\u003ctd\u003eSEK 3.4bn\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eOrders (FY2024)\u003c\/td\u003e\n\u003ctd\u003e-9%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eComponent cost change (2023)\u003c\/td\u003e\n\u003ctd\u003e+8%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003ch2\u003e\n\u003cspan style=\"color: #3BB77E;\"\u003eSame Document Delivered\u003c\/span\u003e\u003cbr\u003eElekta SWOT Analysis\u003c\/h2\u003e\n\u003cp\u003eThis is the actual SWOT analysis document you’ll receive upon purchase—no surprises, just professional quality. The preview below is taken directly from the full report you'll get; buy now to unlock the entire, editable, and structured version ready for immediate use.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Explore-Preview.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e","brand":"MatrixBCG","offers":[{"title":"Default Title","offer_id":56752613228921,"sku":"elekta-swot-analysis","price":10.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0911\/3554\/1625\/files\/elekta-swot-analysis.png?v=1772242962","url":"https:\/\/matrixbcg.com\/products\/elekta-swot-analysis","provider":"MatrixBCG","version":"1.0","type":"link"}